Is Testosterone-Induced Polycythemia Reversible?

Testosterone-induced polycythemia, the overproduction of red blood cells that raises hematocrit above normal levels, is generally reversible once testosterone therapy is stopped or adjusted. Studies on transdermal and injectable testosterone show that hemoglobin and hematocrit return to baseline within roughly three to twelve months of discontinuation. That said, how quickly the reversal happens depends on the testosterone formulation used, individual biology, and whether other conditions are contributing to the elevated blood counts. The picture gets more complicated when you look at how clinicians actually manage the problem in practice, because the most common intervention, therapeutic phlebotomy, is itself under growing scrutiny.

How Testosterone Pushes Red Blood Cell Counts Up

Testosterone raises hematocrit through at least two pathways working in concert. The first involves erythropoietin, the hormone your kidneys release to signal your bone marrow to make more red blood cells. Testosterone boosts erythropoietin production, and it does so quickly: within the first one to three months of therapy, erythropoietin levels rise significantly.¹ The second pathway involves hepcidin, a liver hormone that acts as a gatekeeper for iron. When hepcidin levels are high, iron stays locked in storage and less is available for making hemoglobin. Testosterone suppresses hepcidin, which frees up more iron for red blood cell production.² In one twelve-month study, testosterone suppressed serum hepcidin by about 57% while increasing red blood cell counts by 9% and hemoglobin by 8%.³

Testosterone also appears to make bone marrow progenitor cells more responsive to erythropoietin, so the combination of the two produces a bigger effect than either would alone.⁴ In studies of hypogonadal men with type 2 diabetes, testosterone therapy decreased hepcidin by about 28%, increased erythropoietin by about 21%, and boosted ferroportin expression in cells by roughly 70%, all of which collectively shunt more iron toward new red blood cells.⁵

An interesting wrinkle is that the body partially adapts. After about six months of continued testosterone therapy, erythropoietin and hepcidin levels drift back toward baseline even though hematocrit stays elevated. Researchers have described this as a “recalibration” of the set point: the body settles into a new normal where it tolerates higher hemoglobin without continuing to escalate the hormonal signals that produced the increase.¹ This recalibration is relevant to reversibility, because it implies the body is not locked into an irreversible pattern. Once testosterone is withdrawn, those signaling pathways can reset downward.

What Happens When You Stop Testosterone

The short version: hemoglobin and hematocrit come back down. Pharmacokinetic studies in patients on transdermal testosterone show that blood counts rise for the first five to six months, plateau, and then return to baseline within three to twelve months after discontinuation.⁶ That is a wide window, and the speed of reversal depends on several factors, including which testosterone formulation was being used.

A 2025 study of transgender men who developed erythrocytosis on testosterone therapy found that the formulation made a meaningful difference. People using testosterone cypionate, whether injected every 14 or 28 days, saw a greater drop in both hematocrit and hemoglobin after discontinuation than those using testosterone undecanoate, which is a longer-acting formulation injected roughly every 90 days.⁷ With undecanoate, discontinuation still lowered hematocrit and hemoglobin, but the decrease was smaller, likely because the drug clears the body more slowly and testosterone levels don’t fall as sharply.

This matters practically. If your clinician tells you to stop testosterone for a period to bring your hematocrit down, the type of testosterone you were on influences how quickly you’ll see results. Cypionate and enanthate injections clear faster; undecanoate lingers. Topical gels and patches generally have the most predictable timelines, since they reach steady state faster and wash out of the system more quickly once stopped.

Why Dose Spacing Often Does Not Fix the Problem

A common clinical instinct when hematocrit creeps up is to keep the patient on testosterone but stretch out the time between injections. The logic sounds reasonable: lower the peaks, lower the red cell stimulus. But research suggests this strategy is unreliable. In the same 2025 study of trans men on fortnightly testosterone cypionate, simply spacing out doses did not significantly reduce hematocrit or hemoglobin.⁷ The body was already primed to produce more red blood cells, and a slightly lower average dose wasn’t enough to undo that.

Switching from injections to a transdermal formulation is often more effective than simply spacing doses, because gels and patches deliver a steadier, lower concentration of testosterone without the sharp spikes that injectable forms create. Those peaks are thought to be partly responsible for the higher polycythemia rates seen with injections. But transdermal formulations aren’t risk-free either; they still raise hematocrit in some people, just at a lower rate. The main takeaway is that if your hematocrit is already elevated, adjusting the dosing schedule of the same injectable formulation may not be enough, and a temporary discontinuation or a switch to a different delivery method is more likely to work.

The Phlebotomy Debate

For years, the standard clinical response to testosterone-induced erythrocytosis has been therapeutic phlebotomy: drawing blood to physically remove red blood cells and bring hematocrit down. Guidelines from multiple endocrine societies recommend checking hematocrit periodically and using phlebotomy when it exceeds a threshold, often 54%. But a growing body of opinion within the field questions whether this practice is well supported.

A 2024 review examined the evidence behind phlebotomy for testosterone-induced erythrocytosis and found it wanting. There is little evidence that phlebotomy is effective or safe for this specific condition. The review raised a biological concern: phlebotomy lowers tissue oxygen levels and depletes iron stores, which triggers the body’s oxygen-sensing pathways. In response, the body ramps up erythropoietin to replace the lost red blood cells, potentially creating a cycle. More troublingly, iron depletion from repeated phlebotomy could itself increase thrombotic risk, which is the very outcome phlebotomy is supposed to prevent.⁸

This doesn’t mean phlebotomy is never appropriate. If hematocrit is dangerously high and creating immediate symptoms like headaches, dizziness, or visual changes, drawing blood provides fast relief. But as a routine preventive measure for mildly elevated hematocrit in someone who feels fine, the rationale is thinner than many people assume. The conversation in the field is shifting toward questioning whether testosterone-induced polycythemia even carries the same cardiovascular risk as polycythemia vera (a bone marrow cancer that raises blood counts through a completely different mechanism). The two conditions get lumped together in clinical practice, but the underlying biology is different, and the risk profile may be too.

Who Is Most Likely to Develop Polycythemia on Testosterone

Not everyone on testosterone therapy develops polycythemia. Rates vary across studies, but a reasonable estimate for injectable testosterone is that roughly one in nine users develops a hematocrit above the clinical threshold. Several factors make it more likely.

Obstructive sleep apnea appears to be a significant contributor. In a study of hypogonadal men on testosterone replacement, those who also had sleep apnea were about twice as likely to develop polycythemia, even after adjusting for age, body weight, and testosterone levels.⁹ Sleep apnea causes repeated drops in blood oxygen during the night, which independently stimulates erythropoietin production. Add testosterone’s own erythropoietin-boosting effect on top of that, and the risk compounds. If you develop polycythemia on testosterone, getting screened for sleep apnea is worth doing, because treating the apnea may help manage the blood counts without requiring testosterone to be stopped.

Genetics also play a role. The androgen receptor gene contains a stretch of repeated DNA sequences (a CAG repeat), and the length of this repeat affects how strongly cells respond to testosterone. Men with shorter CAG repeats have more sensitive androgen receptors. A study of long-term testosterone undecanoate therapy found that shorter CAG repeats, combined with higher testosterone levels, significantly predicted hematocrit rising above 50%.¹⁰ In practical terms, this means that two men on identical testosterone doses can have very different hematocrit responses, not because of lifestyle differences but because of how their androgen receptors are wired. There’s no simple clinical test for this in routine practice, but it helps explain why some patients develop polycythemia quickly while others never do.

Other risk factors that show up across studies include higher baseline hematocrit before starting therapy, older age, smoking, and using injectable rather than transdermal formulations. The peak testosterone levels that occur after an injection are higher than what you get with a gel or patch, and those peaks seem to drive more red cell production.

Clomiphene Citrate as a Lower-Risk Alternative

For men whose primary goal is treating hypogonadism and who are worried about polycythemia, clomiphene citrate offers an interesting comparison. Clomiphene is not testosterone itself; it works by blocking estrogen’s feedback signal to the brain, which causes the body to produce more of its own testosterone. The result is a rise in serum testosterone that is comparable to what exogenous testosterone provides, but with a dramatically different effect on red blood cells.

A multi-institutional study compared polycythemia rates in hypogonadal men on testosterone replacement versus clomiphene citrate. The mean rise in hematocrit was 3.0% with testosterone replacement and just 0.6% with clomiphene. The prevalence of polycythemia was 11.2% in the testosterone group compared to 1.7% in the clomiphene group, a statistically significant difference that held even after accounting for age, smoking history, and pretreatment hematocrit.¹¹ The testosterone gains were similar between the two groups, roughly 330 to 370 ng/dL, suggesting the benefit isn’t coming at the cost of less effective hormone treatment.

Why the difference? When you inject exogenous testosterone, blood levels spike well above the physiological range before falling. Those supraphysiological peaks are thought to be a major driver of erythrocytosis. Clomiphene, by contrast, stimulates the body’s own testosterone production, which stays within a more natural range and avoids the peaks and troughs of injections. Clomiphene is not without its own limitations. It is used off-label for male hypogonadism, it doesn’t work for men whose testes can’t respond (primary hypogonadism), and long-term data are more limited. But for the right patient, it sidesteps the polycythemia issue almost entirely.

When to Worry and When Not To

A mildly elevated hematocrit in someone on testosterone therapy is extremely common and does not necessarily signal danger. The evidence connecting testosterone-induced polycythemia to blood clots or cardiovascular events is less clear-cut than clinical guidelines sometimes imply. Part of the confusion comes from extrapolating data on polycythemia vera, where hematocrit levels can climb far higher and the disease itself involves abnormal bone marrow signaling that creates a pro-clotting state. Testosterone-induced erythrocytosis is a different animal: it represents a healthy bone marrow responding to a hormonal signal, and the resulting red blood cells are normal.

That said, there are thresholds where concern is warranted. A hematocrit persistently above 54% is the level at which most guidelines recommend intervention, because blood viscosity increases meaningfully at that point. Symptoms to watch for include persistent headaches, facial flushing, blurred vision, and an unusual sensation of fullness in the head. These can signal that blood viscosity is affecting circulation. If you’re experiencing those symptoms on testosterone therapy, getting your blood count checked promptly makes sense.

For most people, the practical takeaway is that you should have regular blood work, including a complete blood count, when you’re on testosterone therapy. Many clinicians check at three months, six months, and annually thereafter. If your hematocrit starts creeping up, the options in rough order are switching to a transdermal formulation, lowering the dose, temporarily stopping therapy, or in select cases, phlebotomy. Total discontinuation reliably brings counts back down within a few months to a year. The condition is not permanent, and it does not appear to cause lasting damage to the bone marrow or the blood-forming system once the testosterone stimulus is removed.

The Set-Point Question and Long-Term Therapy

One question that comes up among people on long-term testosterone therapy is whether the body eventually adapts and stops overproducing red cells. The set-point research from Source 1 hints at something like this: after about six months, the hormonal signals driving erythrocytosis partially normalize even though testosterone is still being administered.¹ Erythropoietin levels come down from their initial spike, hepcidin suppression eases somewhat, and the system stabilizes at a new, higher hematocrit rather than continuing to climb indefinitely. This plateauing effect is also consistent with the pharmacokinetic observation that hematocrit rises for the first five to six months and then levels off.⁶

This doesn’t mean you can ignore elevated counts. Even a stable, plateaued hematocrit of 55% is worth addressing. But it does mean the body isn’t on a runaway escalator. If your hematocrit stabilizes at, say, 50% on a transdermal gel and you feel well, that may be manageable with monitoring alone. The clinical challenge lies with the subset of patients whose levels continue climbing or who stabilize well above the comfort zone. For that group, the decision tree involves the interventions already described: formulation switches, dose reductions, temporary breaks, or considering alternative treatments like clomiphene. None of these decisions need to be permanent, and none of them imply that the polycythemia has caused irreversible harm. The bone marrow is simply following orders, and once the orders change, it adjusts.